bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.11.758381

Dual blockade of IL-18 and IL-4Rα by a bispecific antibody for improved treatment of atopic dermatitis

Zhang, L.·Meng, Z.·Bo, H.·Tian, Y.·Mou, W.·Ping, X.·Dong, J.·Li, Y. L.
View original source ↗Export metadata ↓

Abstract

Background: Atopic dermatitis (AD) is a chronic inflammatory dermatosis primarily driven by type 2 immunity, with additional type 1 and type 3 components that may limit the benifit of ILRalpha blockade alone. Interleukin18 (IL18), an epithelial alarmin genetically associated with AD and correlated with disease severity, has been implicated as an upstream amplifier of this mixed inflammatory response. Objective: To assess whether concurrent IL18 neutralization and IL4Ralpha; blockade with a bispecific antibody provides broader and more balanced suppression of AD relevant type 1, type 2, and type 3 pathways than single target inhibition. Methods: We generated FJ0125, a bispecific antibody comprising human IL18 binding protein fused to a novel humanized anti IL4Ralpha antibody, and characterized its binding, signaling, and functional activity in vitro and in vivo. The activity was evaluated in human group 2 innate lymphoid cell and primed Th2 cell assays, a keratinocyte & dendritic cell & T cell coculture system, and an MC903/Staphylococcus aureus induced dermatitis model in human IL4/IL4Ralpha; knock in mice. Results: FJ0125 bound to IL18 and IL4Ralpha; with high affinity, engaged both targets, inhibited IL4/IL13 signaling with dupilumab comparable potency, and neutralized human and mouse IL18. In vitro, FJ0125 more effectively suppressed IL18 driven lymphocyte activation and type 1, type 2, and type 3 cytokine production than IL18BPFc or IL4Ralpha; monotherapy. In vivo, FJ0125 reduced multitype cytokines, improved dermatitis, lowered serum IgE, and abrogated the paradoxical IL22 increase observed with selective IL4Ralpha; blockade. Conclusion: Dual IL18/IL4Ralpha; blockade with FJ0125 achieves coordinated suppression of multitype inflammation and represents a mechanistically substantiated therapeutic strategy for AD.

Explore related subjects

immunologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhang, L., Meng, Z., Bo, H., Tian, Y., Mou, W., Ping, X., Dong, J., Li, Y. L.. 2026-10-17. Dual blockade of IL-18 and IL-4Rα by a bispecific antibody for improved treatment of atopic dermatitis. https://doi.org/10.64898/2026.10.11.758381

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Type 1 immunity linked to CMV exposure improves long-term survival in sepsis without shock

Dysregulated immune responses are at the core of sepsis pathology and can drive both acute organ dysfunction and long-term morbidity and mortality. To better understand the association between specific immune histories, perturbations and sepsis outcomes, we combined immune phenotyping, functional cytokine production assays and antibody repertoire profiling. While sepsis immune profiles were highly heterogeneous, we identified a strong association between the frequency of CXCR3-expressing CD4 memory T cells at time of enrollment and six-month survival in sepsis without shock. Surprisingly, the same population was linked to improved organ function trajectories in septic shock patients but did not influence six-month survival, highlighting the importance of considering physiological states to define immune predictors. Finally, phage display profiling revealed that these Th1 cells were generally expanded in CMV-seropositive individuals, suggesting that previous and latent infections may modulate sepsis outcomes.

immunology↗
bioRxiv2026

Innate Immune Dysregulation Precedes Clinical Onset in Neuromyelitis Optica

Neuromyelitis optica spectrum disorder (NMOSD) is a disabling inflammatory central nervous system (CNS) disease characterized by pathogenic aquaporin 4 (AQP4) autoantibodies. The biological events that precede clinical onset remain unknown. In a unique longitudinal NMOSD cohort from the U.S. Department of Defense Serum Repository, with samples collected up to 24 years before onset, we applied discovery proteomics (~5,400 proteins), pan-viral antibody profiling (VirScan), and in silico analyses to characterize preclinical NMOSD versus matched healthy controls. Innate immune activation, particularly CXCL1 elevation, was the dominant immunological feature of preclinical NMOSD, preceding onset by ~12.7 years. AQP4-IgG was detectable more than 3 years before onset, while CNS injury markers increased only after disease manifestation. VirScan identified enhanced CMV-specific antibody reactivity following AQP4- IgG seroconversion, and network analyses revealed interactions between NMOSD-associated and CMV-derived proteins. Together, these findings establish a novel multi-hit model of NMOSD, with implications for understanding antibody-mediated autoimmunity more broadly.

immunology↗
bioRxiv2026

IL-2 and CD40L can establish and sustain a human B cell-mediated immune regulatory network

B cells can control inflammation, but the factors governing B cell-mediated immune regulatory network remain unclear. We report that IL-2/CD40L enable class-switched memory (CSM) B cells to acquire an immunosuppressive phenotype characterized by the expression of surface TIGIT as well as multiple other inhibitory receptors (PD-1, LAG-3, GITR, CD39, and CTLA-4) and soluble molecules (IL-10, granzyme B, and IL-35). TIGIT+ CSM B cells expressing functional CCR9 exhibit significant defects in total immunoglobulin secretion, while preserving IgA2 secretion. Furthermore, IL-2/CD40L-induced ex vivo-generated TIGIT+ CSM B cells suppress human T cell-mediated inflammation in a xenogeneic mouse model of acute graft-versus-host disease, while promoting IL-10-producing regulatory T cell (Treg) response. These findings identify IL-2/CD40L as key drivers of a B cell-mediated immune regulatory network, especially by generating TIGIT+ CSM B cells that can further promote Treg response. This study supports the development of TIGIT+ B cell-based therapy models for inflammatory diseases.

immunology↗